We are live on ! Find out more
PCRX icon

Pacira BioSciences

187 hedge funds and large institutions have $3.03B invested in Pacira BioSciences in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $31.6M | Put options by funds: $24.3M

16% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 63

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

9% less funds holding

Funds holding: 205187 (-18)

15% less capital invested

Capital invested by funds: $3.58B → $3.03B (-$553M)

34% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 47

Holders
187
Holders Change
-18
Holders Change %
-8.78%
% of All Funds
5.04%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
31
Increased
73
Reduced
63
Closed
47
Calls
$31.6M
Puts
$24.3M
Net Calls
+$7.32M
Net Calls Change
+$7.3M
Name Holding Trade Value Shares
Change
Change in
Stake
PPA
101
Parametric Portfolio Associates
Washington
$1.19M -$457K -5,809 -26%
WSA
102
Wall Street Associates
California
$1.15M -$304K -3,858 -19%
PG
103
PEAK6 Group
Illinois
$991K +$1.1M +14,015 New
BG
104
BlackRock Group
United Kingdom
$990K -$45K -571 -4%
DCM
105
Driehaus Capital Management
Illinois
$957K -$3.22M -40,902 -75%
TAM
106
Tocqueville Asset Management
New York
$902K -$199K -2,530 -17%
Susquehanna International Group
107
Susquehanna International Group
Pennsylvania
$847K -$998K -12,668 -51%
Group One Trading
108
Group One Trading
Illinois
$816K -$327K -4,149 -26%
AQR Capital Management
109
AQR Capital Management
Connecticut
$757K -$64.4K -818 -7%
NERM
110
New England Research & Management
Illinois
$690K +$501K +6,360 +187%
ARTA
111
A.R.T. Advisors
New York
$665K -$2.06M -26,219 -74%
MCTIC
112
MacGuire Cheswick & Tuttle Investment Counsel
Connecticut
$609K
PNC Financial Services Group
113
PNC Financial Services Group
Pennsylvania
$598K +$290K +3,687 +78%
M&T Bank
114
M&T Bank
New York
$538K -$160K -2,029 -21%
NSAM
115
North Star Asset Management
Wisconsin
$523K +$181K +2,300 +45%
Public Employees Retirement Association of Colorado
116
Public Employees Retirement Association of Colorado
Colorado
$498K
DC
117
Deere & Company
Illinois
$490K +$137K +1,738 +33%
TFCP
118
Twin Focus Capital Partners
Massachusetts
$482K
Legal & General Group
119
Legal & General Group
United Kingdom
$459K +$24.6K +312 +5%
Principal Financial Group
120
Principal Financial Group
Iowa
$444K -$26.1K -331 -5%
GPC
121
Glacier Peak Capital
Washington
$442K +$492K +6,250 New
CG
122
Clinton Group
New York
$438K -$190K -2,410 -28%
Comerica Bank
123
Comerica Bank
Texas
$422K +$234K +2,972 +99%
PCM
124
Palisade Capital Management
New Jersey
$389K +$98.4K +1,250 +29%
PA
125
Profund Advisors
Maryland
$365K +$8.98K +114 +2%

PCRX Hedge Fund Activity: Q2 2015 in Review

187 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2015, worth a combined $3.03B — down 15% from $3.58B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of PCRX and 31 opened new positions — a net loss of 16 holders — while 63 trimmed existing stakes and 73 added.

The largest buyer was Janus Henderson Investors US, adding an estimated $124M. The largest seller was Jennison Associates, cutting an estimated $92.5M.

  • 187 institutional investors held Pacira BioSciences (PCRX) as of Q2 2015, down from 205 in Q1 2015.
  • Funds reported $3.03B of Pacira BioSciences stock for Q2 2015, down 15% quarter-over-quarter.
  • 31 funds opened new Pacira BioSciences positions in Q2 2015 and 47 closed out, a net change of -16 holders.
  • The largest Pacira BioSciences buyer in Q2 2015 was Janus Henderson Investors US, an estimated $124M added.
  • The largest Pacira BioSciences seller in Q2 2015 was Jennison Associates, an estimated $92.5M sold.

Based on aggregated 13F filings for Q2 2015.